MAX
Company Analysis NeuroSense Therapeutics Ltd.
1. Summary
Advantages
- Price (0.92 $) is less than fair price (1.27 $)
Disadvantages
- Dividends (0%) are below the sector average (0.53%).
- The stock's return over the last year (-22.01%) is lower than the sector average (14.95%).
- Current debt level 1.6% has increased over 5 years from 0%.
- The company's current efficiency (ROE=-2880.11%) is lower than the sector average (ROE=104.24%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| NeuroSense Therapeutics Ltd. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -0.9% | -12.1% | 0.5% |
| 90 days | -18.8% | 8% | -0.5% |
| 1 year | -22% | 14.9% | 15.6% |
NRSN vs Sector: NeuroSense Therapeutics Ltd. has significantly underperformed the "Healthcare" sector by -36.95% over the past year.
NRSN vs Market: NeuroSense Therapeutics Ltd. has significantly underperformed the market by -37.65% over the past year.
Stable price: NRSN is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: NRSN with weekly volatility of -0.42% over the past year.
3. Summary of the report
5. Fundamental Analysis
5.1. Stock price and price forecast
Below fair price: The current price (0.92 $) is lower than the fair price (1.27 $).
Price significantly below the fair price: The current price (0.92 $) is 38% lower than the fair price.
5.2. P/E
P/E vs Sector: The company's P/E (-2.17) is lower than that of the sector as a whole (36.09).
P/E vs Market: The company's P/E (-2.17) is higher than that of the market as a whole (-104.3).
5.3. P/BV
P/BV vs Sector: The company's P/BV (8.64) is lower than that of the sector as a whole (254.48).
P/BV vs Market: The company's P/BV (8.64) is lower than that of the market as a whole (72.17).
5.3.1 P/BV Similar companies
5.5. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (127.4).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (114).
5.5.1 P/S Similar companies
5.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-1.93) is higher than that of the sector as a whole (-27.32).
EV/Ebitda vs Market: The company's EV/Ebitda (-1.93) is higher than that of the market as a whole (-78.04).
6. Profitability
6.1. Profitability and revenue
6.2. Earnings per share - EPS
6.3. Past profitability Net Income
Yield Trend: Rising and has grown by 61.68% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (61.68%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (435.8%).
6.4. ROE
ROE vs Sector: The company's ROE (-2880.11%) is lower than that of the sector as a whole (104.24%).
ROE vs Market: The company's ROE (-2880.11%) is lower than that of the market as a whole (-6.22%).
6.6. ROA
ROA vs Sector: The company's ROA (-263.45%) is lower than that of the sector as a whole (-2.25%).
ROA vs Market: The company's ROA (-263.45%) is lower than that of the market as a whole (38.45%).
6.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (1.17%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (9.79%).
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
8. Dividends
8.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.53%.
8.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
8.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Based on sources: porti.ru
